Citations

Showing 10 of 108081 citations.

Decompressive Hemicraniectomy in the Setting of Poststroke Cerebral Edema: A Case for Early Intervention
Aoun, Rami James N. , Gupta, Aman , Welz, Matthew E., Bendok, Bernard R.

Mayo Clinic

Neurosurgery | May 23, 2017 | Volume: 81 | Issue: 1 | Pages: N11-N13

10.1093/neuros/nyx252 | PMID 28873989 Get It

Correction for Evans et al., “Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III”
Hujer, Andrea M. , Jiang, Hongyu , Hill, Carol , Hujer, Kristine M., Mediavilla, José R. , Tran, Thuy Tien T., Higgins, Paul G. , Kreiswirth, Barry N. , Patel, Robin , Chen, Liang , Sampath, Rangarajan , Marzan, Christine, Fowler, Vance G. , Chambers, Henry F. , Evans, Scott , Manca, Claudia , Domitrovic, Tatiana , Seifert, Harald , Kreiswirth, Barry N , Jacobs, Michael R. , Chen, Liang , Hall, Thomas A. , Fowler, Vance G. , Bonomo, Robert A. , Patel, Robin , Evans, Scott R

Mayo Clinic

Journal of Clinical Microbiology | May 23, 2017 | Volume: 55 | Issue: 6 | Pages: 1970-1970

10.1128/jcm.00525-17 | PMID 28536161 Get It

Analyses of thrombi in acute ischemic stroke: A consensus statement on current knowledge and future directions
Andersson, Tommy , Baxter, Blaise, Brouwer, Patrick A. , Brinjikji, Waleed , Costalat, Vincent , Dávalos, Antoni , Demchuk, Andrew M. , Dippel, Diederik W.J. , Fischer, Urs , Gilvarry, Michael , Gounis, Matthew J. , Gralla, Jan , Jansen, Olav , Kallmes, David F. , Khatri, Pooja , López‐Cancio, Elena , Majoie, Charles B.L.M. , Marquering, Henk A. , Narata, Ana Paula , Siddiqui, Adnan H. , Szikora, István , Vale, David, Hacke, Werner , Liebeskind, David S. , Kallmes, David, De Meyer, Simon F , Bendszus, Martin , Campbell, Bruce , Fiehler, Jens , Jovin, Tudor G. , Lees, Kennedy R. , Nogueira, Raul G. , Ringleb, Peter Arthur , Kummer, Rüdiger von , Yoo, Albert J. , Liebeskind, David S. , Siddiqui, Adnan H , Szikora, Istvan , Andersson, Tommy , Demchuk, Andrew M , Brouwer, Patrick , Fischer, Urs , Marquering, Henk A , Majoie, Charles B L M , Khatri, Pooja

Mayo Clinic

International Journal of Stroke | May 23, 2017 | Volume: 12 | Issue: 6 | Pages: 606-614

10.1177/1747493017709671 | PMID 28534706 Get It

Limited data exist on clot composition and detailed characteristics of arterial thrombi associated with large vessel occlusion in acute ischemic stroke. Advances in endovascular thrombectomy and related imaging modalities have created a unique opportunity to analyze thrombi removed from cerebral arteries. Insights into thrombus composition, etiology, physical properties and neurovascular interactions may lead to future advancements in acute ischemic stroke treatment and improved clinical outcomes. Advances in imaging techniques may enhance clot characterization and inform therapeutic decision-making prior to treatment and reveal stroke etiology to guide secondary prevention. Current imaging techniques can provide some information about thrombi, but there remains much to evaluate about relationships that may exist among thrombus composition, occlusion characteristics and treatment outcomes. Improved pathophysiological characterization of clot types, their properties and how these properties change over time, together with clinical correlates from ongoing studies, may facilitate revascularization with thrombolysis and thrombectomy. Interdisciplinary approaches covering clinical, engineering and scientific aspects of thrombus research will be key to advancing the understanding of thrombi and improving acute ischemic stroke therapy. This consensus statement integrates recent research on clots and thrombi retrieved from cerebral arteries and provides a rationale for further analyses, including current opportunities and limitations.
Cervicomedullary compression as the main manifestation of wild-type transthyretin amyloidosis
Rezania, Kourosh , Pytel, Peter , Highsmith, W. Edward, Gabikian, Patrik

Mayo Clinic

Amyloid | May 23, 2017 | Volume: 24 | Issue: 2 | Pages: 133-134

10.1080/13506129.2017.1331907 | PMID 28532173 Get It

The Role of Temporary Fecal Diversion
Pembérton, John H., Lightner, Amy L.

Mayo Clinic

Clinics in Colon and Rectal Surgery | May 23, 2017 | Volume: 30 | Issue: 03 | Pages: 178-183

10.1055/s-0037-1598158 | PMID 28684935 Get It

AbstractThe use of temporary fecal diversion is of great importance to tenuous anastomosis, immunosuppressed patient, or actively infected patient. Its use protects newly constructed intestinal anastomoses from being the culprit of pelvic sepsis or systemic illness. Thus, potential morbidity and mortality can be averted. However, its appropriate or optimal use is often debated. We herein discuss the evidence for when to best use a diverting stoma for colorectal, coloanal, and ileoanal anastomoses. We also discuss the importance of considering a temporary diverting stoma in the setting of high-dose immunosuppression (e.g., transplant patients or inflammatory bowel disease), active infection, or upon creation of ileal pouch–anal anastomosis. Lastly, we discuss the advantages and disadvantages of a loop ileostomy versus colostomy for temporary diversion of fecal contents.
Family history and TOMM40 '523 interactive associations with memory in middle‐aged and Alzheimer's disease cohorts
Willette, Auriel A. , Webb, J. L. , Lutz, Michael W. , Bendlin, Barbara B. , Wennberg, Alexandra , Oh, Jennifer M. , Roses, Allen D., Koscik, Rebecca L. , Dowling, N. Maritza , Asthana, Sanjay , Asthana, Sanjay , Wennberg, Alexandra M, Hermann, Bruce P. , Johnson, Sterling C. , Wennberg, Alexandra M V

Mayo Clinic

Alzheimer's & Dementia | May 23, 2017 | Volume: 13 | Issue: 11 | Pages: 1217-1225

10.1016/j.jalz.2017.03.009 | PMID 28549947 Get It

AbstractIntroductionFamily history (FH) of Alzheimer's disease (AD) affects mitochondrial function and may modulate effects of translocase of the outer mitochondrial membrane 40 kDa (TOMM40) rs10524523 ('523) poly‐T length on memory decline.MethodsFor 912 nonapolipoprotein ε4 middle‐aged adults and 365 aged adults across the AD spectrum, linear mixed models gauged FH and TOMM40 '523 interactions on memory and global cognition between baseline and up to 10 years later. A cerebrospinal fluid mitochondrial function biomarker was also assessed.ResultsFor FH negative participants, gene‐dose preservation of memory and global cognition was seen for “very long” versus “short” carriers. For FH positive, an opposite gene‐dose decline was seen for very long versus short carriers. Maternal FH was a stronger predictor in aged, but not middle‐aged, participants. Similar gene‐dose effects were seen for the mitochondrial biomarker aspartate aminotransferase.DiscussionThese results may clarify conflicting findings on TOMM40 poly‐T length and AD‐related decline.
Chronic subthreshold cortical stimulation: a therapeutic and potentially restorative therapy for focal epilepsy
Stead, Matt, Lundstrom, Brian Nils, Lundstrom, Brian N. , Worrell, Gregory A. , Gompel, Jamie J. Van

Mayo Clinic

Expert Review of Neurotherapeutics | May 23, 2017 | Volume: 17 | Issue: 7 | Pages: 661-666

10.1080/14737175.2017.1331129 | PMID 28532252 Get It

Coadministration of Liposomal Amphotericin B and Contrast Medium Does Not Increase Risk of Kidney Injury
O’Horo, John C. , Osmon, Douglas R. , Saleh, Omar Abu , Marcelin, Jasmine R , Gharaibeh, Kamel A. , Hamadah, Abdurrahman , Barwise, Amelia , Kayhart, Bryce M., McDonald, Robert J. , McDonald, Jennifer S. , Leung, Nelson , Marcelin, Jasmine , Barwise, Amelia K , O'Horo, John C

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 23, 2017 | Volume: 61 | Issue: 8 | Pages: No page available

10.1128/aac.00323-17 | PMID 28533242 Get It

ABSTRACT Intravenous radiographic contrast medium and amphotericin B are commonly required in the care of patients with fungal infections. Both interventions have proposed nephrotoxicity through similar mechanisms. We systematically examined patients who received coadministration of liposomal amphotericin B (AmBisome; GE Healthcare) and intravenous contrast medium within a 24-h period and compared the results for those patients with the results for patients who underwent non-contrast medium studies. We found 114 cases and 85 controls during our study period. Overall, no increased risk of renal injury was seen with coadministration of these 2 agents. Adjustment for age, baseline kidney function, and other clinical factors through propensity score adjustment did not change this result. Our observations suggest that, when clinically indicated, coadministration of contrast medium and liposomal amphotericin B does not present excess risk compared with that from the administration of liposomal amphotericin B alone.
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia
Papaioannou, Dimitrios , Shen, Changxian , McNeil, Betina, Bill, Marius , Karunasiri, Malith, Burke, Matthew H. , Özer, Hatice Gülçin , Yilmaz, Selen, Zitzer, Nina C. , Behbehani, Gregory K. , Oakes, Christopher C. , Steiner, Damian J., Marcucci, Guido , Powell, Bayard L., Kolitz, Jonathan E. , Carter, Thomas H. , Wang, Eunice S. , Mrózek, Krzysztof , Bloomfield, Clara D. , Garzon, Ramiro , Dorrance, Adrienne M. , Nicolet, Deedra , Wang, Eunice S. , Croce, Carlo Maria , Caligiuri, Michael A.

Mayo Clinic

Proceedings of the National Academy of Sciences | May 22, 2017 | Volume: 114 | Issue: 23 | Pages: No page available

10.1073/pnas.1703142114 | PMID 28533390 Get It

Significance In this work we report on the previously uncharacterized clinical and biological role for EGFL7 in acute myeloid leukemia (AML). Patients with increased EGFL7 mRNA expression had lower complete remission rates and shorter overall and event-free survival, demonstrating the clinical relevance of EGFL7 expression in cytogenetically normal AML. Our results show that AML blasts are able to synthesize and secrete EGFL7 protein, promoting autocrine blast cell growth. Inhibition of EGFL7 results in decreased proliferation and induces apoptosis of AML cells. Taken together, our data provide the rationale for targeting EGFL7 using blocking antibodies as a therapy for patients with AML.
IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831
Reinholz, Monica M., Chen, Beiyun, Dueck, Amylou C. , Tenner, Kathleen , Riehle, Darren, Jenkins, Robert B. , Geiger, Xochiquetzal J., McCullough, Ann E. , Perez, Edith A. , Ballman, Karla, Dueck, A. C. , Ballman, Karla V.

Mayo Clinic

Clinical Cancer Research | May 22, 2017 | Volume: 23 | Issue: 15 | Pages: 4203-4211

10.1158/1078-0432.ccr-15-0574 | PMID 28533226 Get It

Abstract Background: Preclinical evidence indicates that increased insulin-like growth factor receptor-1 (IGF1R) signaling interferes with the action of trastuzumab suggesting a possible mechanism of trastuzumab resistance. Thus, we evaluated IGF1R prevalence, relationship with demographic data, and association with disease-free survival (DFS) of patients randomized to chemotherapy alone (Arm A) or chemotherapy with sequential (Arm B) or concurrent trastuzumab (Arm C) in the prospective phase III HER2+ adjuvant N9831 trial. Experimental Design: IGF1R protein expression was determined in tissue microarray sections (three cores per block; N = 1,197) or in whole tissue sections (WS; N = 537) using IHC (rabbit polyclonal antibody against IGF1R β-subunit). A tumor was considered positive (IGF1R+) if any core or WS had ≥1+ membrane staining in >0% invasive cells. Median follow-up was 8.5 years. Results: Of 1,734 patients, 708 (41%) had IGF1R+ breast tumors. IGF1R+ was associated with younger age (median 48 vs. 51, P = 0.007), estrogen receptor/progesterone receptor positivity (78% vs. 35%, P < 0.001), nodal positivity (89% vs. 83%, P < 0.001), well/intermediate grade (34% vs. 24%, P < 0.001), tumors ≥2 cm (72% vs. 67%, P = 0.02) but not associated with race or tumor histology. IGF1R did not affect DFS within arms. Between Arms A and C, patients with IGF1R+ and IGF1R− tumors had DFS HRs of 0.48 (P ≤ 0.001) and 0.68 (P = 0.009), respectively (Pinteraction = 0.17). Between Arms A and B, patients with IGF1R+ and IGF1R− tumors had DFS HRs of 0.83 (P = 0.25) and 0.69 (P = 0.01), respectively (Pinteraction = 0.42). Conclusions: In contrast to preclinical studies that suggest a decrease in trastuzumab sensitivity in IGF1R+ tumors, our adjuvant data show benefit of adding trastuzumab for patients with either IGF1R+ and IGF1R− breast tumors. Clin Cancer Res; 23(15); 4203–11. ©2016 AACR.